Lever Bio, a Turin, Italy-based immuno-oncology company, raised €4M in funding.
The round was led by Claris Ventures.
The company intends to use the funds to further progress the assets through preclinical development and validate their therapeutic potential and positioning in solid tumors.
Led by Chiara Donini, Project Manager, Lever Bio is a biotechnology company focused on developing new immuno-oncology therapies. By leveraging metabolic and immune system reprogramming, the company aims to overcome resistance to existing cancer treatments, particularly in solid tumors. Through strategic in-licensing agreements and collaborations with leading research institutions, it is dedicated to advancing novel biologics to improve patient outcomes.
The company also announced a strategic partnership with VIB, a life sciences research institute in Belgium, securing access to VIB’s key intellectual property (IP) to further develop and finance four novel VHH antibody-based therapies. The collaboration leverages the expertise of Professor Massimiliano Mazzone, an internationally recognized leader in tumor immunology and immuno-metabolism, and his team at the VIB-KU Leuven Center for Cancer Biology.
FinSMEs
28/05/2025